Expression of the EP4 Prostaglandin E2 Receptor Subtype with Rat Dextran Sodium Sulphate Colitis: Colitis Suppression by a Selective Agonist, ONO-AE1-329-Reference-Cited by-同舟云学术

Expression of the EP4 Prostaglandin E2 Receptor Subtype with Rat Dextran Sodium Sulphate Colitis: Colitis Suppression by a Selective Agonist, ONO-AE1-329

Published:2002-06-28 Issue:1 Volume:56 Page:66-75
ISSN:0300-9475
Container-title:Scandinavian Journal of Immunology
language:en
Short-container-title:

Author:

Nitta M.,Hirata I.,Toshina K.,Murano M.,Maemura K.,Hamamoto N.,Sasaki S.,Yamauchi H.,Katsu K.

Publisher

Wiley

Subject

Immunology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-3083.2002.01096.x/fullpdf

Reference48 articles.

1. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease;Stevens;Dig Dis Sci,1992

2. Cytokines in inflammatory bowel disease;Rogler;World J Surg,1998

3. Letter: prostaglandins, ulcerative colitis, and sulphasalazine;Gould;Lancet,1975

4. Prevention, through cytoprotection, of clindamycin-induced colitis in hamsters with 16,16-demetyl PGE2;Robert;Gastroenterology,1980

5. Inhibition of Butyric Acid-Induced Colitis in Mice by 16,16-Dimethyl Prostaglandin E2;McCafferty;Agents Actions,1992

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of NXT-10796, an orally active, intestinally restricted EP4 agonist prodrug for the treatment of inflammatory bowel disease;Bioorganic & Medicinal Chemistry Letters;2023-07

2. The effect of tuina on ulcerative colitis model mice analyzed by gut microbiota and proteomics;Frontiers in Microbiology;2022-11-29

3. Optimization and validation of polyherbal formulation by applying Box-Behnken design for the treatment of Inflammatory bowel disease in experimental animals.;Current Drug Therapy;2021-12-20

4. Eicosanoid Pathway Modulators: Prostaglandins, Prostacyclin, and Thromboxane;Burger's Medicinal Chemistry and Drug Discovery;2021-04-28

5. Bioactive lipids in inflammatory bowel diseases – From pathophysiological alterations to therapeutic opportunities;Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids;2021-02